QTTB
Q32 Bio Inc. NASDAQ Listed Mar 28, 2018$13.17
+10.21%
vs $11.95
Mkt Cap $162.2M
52w Low $1.36
93.4% of range
52w High $14.00
50d MA $8.69
200d MA $4.95
P/E (TTM)
4.9x
EV/EBITDA
5.3x
P/B
3.9x
Debt/Equity
0.4x
ROE
71.0%
P/FCF
-6.7x
RSI (14)
50.40
ATR (14)
$1.38
Beta
-1.02
50d MA
$8.69
200d MA
$4.95
Avg Volume
1.2M
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
830 Winter Street · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | -0.68 | -0.54 | +20.6% | 5.14 | -0.8% | +6.4% | -0.5% | -1.3% | -3.5% | +12.2% | — |
| Mar 10, 2026 | AMC | -0.85 | 3.65 | +529.4% | 5.99 | +0.0% | +15.4% | +1.9% | -3.1% | -7.6% | -2.7% | — |
| Nov 13, 2025 | AMC | -1.39 | -0.60 | +56.8% | 2.21 | -4.5% | -2.3% | +6.0% | -0.4% | -7.0% | -9.0% | — |
| Aug 6, 2025 | AMC | -1.14 | -0.78 | +31.6% | 1.95 | -1.5% | -8.2% | -8.9% | +9.8% | -6.1% | +7.7% | — |
| May 8, 2025 | AMC | -1.23 | -0.90 | +26.8% | 1.54 | +1.3% | +0.6% | +7.1% | +4.8% | -5.2% | +5.5% | — |
| Mar 11, 2025 | AMC | -1.25 | -1.16 | +7.2% | 1.90 | +1.1% | +0.0% | -3.2% | +8.7% | +9.5% | -2.3% | — |
| Nov 7, 2024 | AMC | -1.41 | -1.46 | -3.5% | 47.46 | +0.6% | -4.6% | -0.6% | -3.0% | -9.0% | -10.3% | — |
| Aug 8, 2024 | AMC | -1.00 | -1.42 | -42.0% | 35.83 | -0.1% | -3.9% | +4.3% | -0.7% | +1.9% | +0.9% | — |
| May 9, 2024 | AMC | -1.42 | -13.15 | -826.1% | 26.80 | -1.0% | +1.2% | +2.3% | +2.4% | +3.4% | +5.4% | — |
| Mar 13, 2024 | AMC | -0.30 | -0.28 | +6.7% | 16.38 | -0.2% | +1.9% | -1.3% | -1.7% | +0.0% | +0.6% | — |
| Nov 14, 2023 | AMC | -0.42 | -0.57 | -35.7% | 18.36 | -4.3% | -13.7% | -35.0% | -2.1% | -1.0% | +1.0% | — |
| Jul 27, 2023 | AMC | -8.55 | -10.98 | -28.4% | 16.92 | +23.4% | +41.5% | +4.5% | +2.9% | -8.4% | +6.1% | — |
| Mar 30, 2023 | TNS | -9.54 | -9.00 | +5.7% | 17.05 | +0.3% | +8.7% | -2.9% | +1.0% | -1.0% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18 | Cantor Fitzgerald | Initiates | Overweight | — | $6.30 | $6.30 | +0.0% | -8.7% | +5.6% | -6.6% | -3.0% | +5.5% |
| Mar 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.90 | $1.92 | +1.1% | +0.0% | -3.2% | +8.7% | +9.5% | -2.3% |
| Feb 11 | BMO Capital | Downgrade | Outperform → Market Perform | — | $3.18 | $2.83 | -11.0% | -9.4% | -7.6% | +0.8% | -0.4% | -2.2% |
| Feb 11 | Piper Sandler | Downgrade | Overweight → Neutral | — | $3.18 | $2.83 | -11.0% | -9.4% | -7.6% | +0.8% | -0.4% | -2.2% |
| Dec 12 | BMO Capital | Maintains | Outperform → Outperform | — | $5.95 | $5.95 | +0.0% | -28.6% | -12.9% | -5.4% | -2.0% | -8.7% |
| Dec 12 | Guggenheim | Downgrade | Buy → Neutral | — | $5.95 | $5.95 | +0.0% | -28.6% | -12.9% | -5.4% | -2.0% | -8.7% |
| Dec 11 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $24.41 | $8.00 | -67.2% | -75.6% | -28.6% | -12.9% | -5.4% | -2.0% |
| Dec 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.41 | $8.00 | -67.2% | -75.6% | -28.6% | -12.9% | -5.4% | -2.0% |
| Dec 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $24.41 | $8.00 | -67.2% | -75.6% | -28.6% | -12.9% | -5.4% | -2.0% |
| Dec 11 | Raymond James | Downgrade | Strong Buy → Outperform | — | $24.41 | $8.00 | -67.2% | -75.6% | -28.6% | -12.9% | -5.4% | -2.0% |
| Dec 11 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $24.41 | $8.00 | -67.2% | -75.6% | -28.6% | -12.9% | -5.4% | -2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2026 | ORBIMED ADVISORS LLCDir | — | Buy | 625,000 | $8.00 | $5.0M | 625,000 | +8.40% | -8.24% |
| May 28, 2026 | ORBIMED ADVISORS LLCDir | — | Buy | 1,250,000 | $8.00 | $10.0M | 3,502,987 | +8.40% | -8.24% |
| May 28, 2026 | Xu DiyongDir | — | Buy | 625,000 | $8.00 | $5.0M | 625,000 | +8.40% | -8.24% |
| May 28, 2026 | Xu DiyongDir | — | Buy | 1,250,000 | $8.00 | $10.0M | 3,502,987 | +8.40% | -8.24% |
8-K · 1.01
!! High
Q32 Bio Inc. -- 8-K 1.01: Material Agreement
Q3 Bio raised capital through a public offering selling shares at $8.00 and pre-funded warrants at $7.9999, providing immediate equity access with minimal exercise costs for investors.
May 27
8-K · 2.02
!! High
Q32 Bio Inc. -- 8-K 2.02: Earnings Results
Q32 Bio reported Q1 2026 results and provided a corporate update, allowing investors to assess the clinical-stage biotech's financial position and progress toward its pipeline development goals.
May 5
8-K
Q32 Bio Inc. -- 8-K Filing
Q3 Bio Inc.'s Form S-3 registration statement became effective April 21, 2025, enabling the company to raise capital through future securities offerings.
Apr 24
8-K
Unknown — 8-K Filing
Qurate Retail Group (QTTB) registered shares for potential sale under an at-the-market offering, creating dilution risk for existing shareholders if the company chooses to raise capital this way.
Mar 27
8-K
Unknown — 8-K Filing
Q32 Bio's upcoming 36-week topline results for bempikibart in alopecia areata represent a critical near-term catalyst that could validate the drug candidate and significantly impact the stock's valuation.
Mar 10
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Atlas Venture Life Science Advisors, Llc | 2,092,106 | $13M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 306,401 | $2M | New | Mar 2026 |
| 3 | Renaissance Technologies Llc | 206,915 | $1M | Added | Mar 2026 |
| 4 | Acadian Asset Management Llc | 172,586 | $1M | Added | Mar 2026 |
| 5 | Pfizer Inc | 101,618 | $737K | Reduced | Mar 2026 |
| 6 | Opaleye Management Inc. | 213,363 | $708K | New | Dec 2025 |
| 7 | Marshall Wace, Llp | 52,440 | $337K | New | Mar 2026 |
| 8 | Two Sigma Investments, Lp | 42,346 | $272K | Reduced | Mar 2026 |
| 9 | Adar1 Capital Management, Llc | 35,000 | $225K | New | Mar 2026 |
| 10 | Monaco Asset Management Sam | 50,919 | $169K | Reduced | Dec 2025 |
| 11 | Northern Trust Corp | 25,033 | $161K | — | Mar 2026 |
| 12 | Citadel Advisors Llc | 15,481 | $99K | Reduced | Mar 2026 |
| 13 | Jane Street Group, Llc | 25,374 | $84K | New | Dec 2025 |
| 14 | Eversource Wealth Advisors, Llc | 5,750 | $78K | Reduced | Mar 2026 |
| 15 | Morgan Stanley | 10,956 | $36K | Reduced | Dec 2025 |
| 16 | Fmr Llc | 3,400 | $22K | Added | Mar 2026 |
| 17 | Royal Bank Of Canada | 2,744 | $18K | Added | Mar 2026 |
| 18 | Arax Advisory Partners | 1,148 | $7K | Added | Mar 2026 |
| 19 | Rockefeller Capital Management L.p. | 577 | $4K | — | Mar 2026 |
| 20 | Russell Investments Group, Ltd. | 454 | $3K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 57,067 | $260K | Feb 2026 |
| 2 | Ultra-Small Company Fund | 12,613 | $81K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 16,801 | $77K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 13,682 | $62K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 6,497 | $30K | Feb 2026 |
| 6 | Knights of Columbus U.S. ALL CAP INDEX FUND | 37 | $144 | Jan 2026 |
| 7 | Guggenheim Active Allocation Fund | 13 | $59 | Feb 2026 |
Valuation
Market Cap
$162.2M
Enterprise Value
$117.4M
P/E (TTM)
4.88x
Forward P/E
—
PEG Ratio
-0.01x
P/B
3.86x
P/S
3.02x
P/FCF
-6.71x
EV/EBITDA
5.30x
Shares Out
12.3M
Financials (TTM)
Revenue
$53.7M
Net Income
$33.2M
EBITDA
$22.2M
Free Cash Flow
-$24.2M
Op Cash Flow
-$33.5M
EPS Basic
$2.42
EPS Diluted
$2.66
EPS Forward
$-2.09
Gross Margin
99.3%
Op Margin
39.8%
Net Margin
61.9%
Balance Sheet
Total Assets
$61.8M
Total Liab.
$19.8M
Total Equity
$42.0M
Cash
$48.3M
LT Debt
$3.5M
Book Value/Sh
$3.42
Debt/Equity
0.37x
Current Ratio
4.85
Quick Ratio
4.85
Returns & Growth
ROE
71.0%
ROA
48.3%
ROIC
29.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+147.3%
Price Returns
2W
+76.8%
1M
+97.3%
3M
+142.3%
6M
+404.6%
12M
+538.7%
Technicals
52W High
$14.00
52W Low
$1.36
50d MA
$8.69
200d MA
$4.95
RSI (14)
50.40
ATR (14)
$1.38
Beta
-1.02
Avg Volume
1.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$13.00
High
$13.00
Low
$13.00
Median
$13.00
Data updated apr 26, 2026 9:40pm
· Source: financialmodelingprep.com